Microbix Biosystems Inc T.MBX

RE:Microbix Announces Closing of Offering and Private Placement

[RazeKreations]

Here is the rest of the story
i messed up on the last post

The securities offered have not been, nor will they be, registered under the US Securities Act, and may not

be offered or sold in the United States or to, or for the account or benefit of, U.S. persons absent

registration or an applicable exemption from the registration requirements. This press release shall not

constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities

in any State in which such offer, solicitation or sale would be unlawful. 

About Microbix Biosystems

Microbix develops proprietary biological technology solutions for human health and well-being, with

about 90 skilled employees and sales growing from a base of over $1 million per month. It makes a wide

range of critical biological materials for the global diagnostics industry, notably antigens for

immunoassays and its laboratory quality assessment products (QAPs™) that support clinical lab

proficiency testing, enable assay development and validation, or help ensure the quality of clinical

diagnostic workflows. Microbix antigens enable the antibody tests of over 100 international diagnostics

companies, while its QAPs are sold to clinical laboratory accreditation organizations, diagnostics

companies, and clinical laboratories. Microbix QAPs are now available in over 30 countries, distributed by

1WA (Oneworld Accuracy Inc.), Alpha-Tec Systems, Inc., Diagnostic International Distribution SpA.,

Labquality Oy, The Medical Supply Company of Ireland, R-Biopharm AG, and Seegene Canada Inc.

Microbix is ISO 9001 and 13485 accredited, U.S. FDA registered, Australian TGA registered, Health Canada

establishment licensed, and provides CE marked products. 

Microbix also applies its biological expertise and infrastructure to develop other proprietary products and

technologies, most notably viral transport medium (DxTM™) to stabilize patient samples for lab-based

molecular diagnostic testing and Kinlytic® urokinase, a biologic thrombolytic drug used to treat blood

clots. Microbix is traded on the TSX and OTCQB, and headquartered in Mississauga, Ontario, Canada. 

Forward-Looking Information

This news release includes “forward-looking information,” as such term is defined in applicable securities

laws. Forward-looking information includes, without limitation, all discussion regarding the Offering and

concurrent Private Placement, use of proceeds of the Offering and Placement, Microbix’s business and

business results, goals or outlook, risks associated with financial results and stability, development

projects such as those referenced in its corporate presentation, regulatory compliance and approvals,

sales to domestic or foreign jurisdictions, engineering and construction, production (including control

over costs, quality, quantity and timeliness of delivery), foreign currency and exchange rates, maintaining

adequate working capital and raising further capital on acceptable terms or at all, and other similar

statements concerning anticipated future events, conditions or results that are not historical facts. These

statements reflect management’s current estimates, beliefs, intentions and expectations; they are not

guarantees of future performance. The Company cautions that all forward looking information is

inherently uncertain and that actual performance may be affected by a number of material factors, many

of which are beyond the Company’s control. Accordingly, actual future events, conditions and results may

differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the

forward-looking information. All statements are made as of the date of this news release and represent

the Company’s judgement as of the date of this new release, and the Company is under no obligation to

update or alter any forward-looking information.  

Please visit www.microbix.com or www.sedar.com for recent Microbix news and filings. 

For further information, please contact Microbix at:

Cameron Groome, CEO 

[phone]

Jim Currie, CFO

[phone] 

Deborah Honig, Investor Relations  

Adelaide Capital Markets

[phone]    [e-mail] 

Copyright © 2021 Microbix Biosystems Inc.      

Microbix®, DxTM™, Kinlytic®, PROCEEDx™,  QAPs™, and REDx™ are trademarks of Microbix Biosystems Inc.